Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.55 |
| ▸ | CES1 | P23141 | 3/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | SNCA | P37840 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6701469 | 1.00 | CES2 (0.55) | CES2CES1L3MBTL1KDM4EMAPT | |
| SCHEMBL6701884 | 1.00 | CES2 (0.55) | CES2CES1L3MBTL1KDM4EMAPT | |
| SCHEMBL15761173 | 0.84 | CES2 (0.47) | CES2CES1L3MBTL1KDM4EMAPT | |
| SCHEMBL6700710 | 0.81 | CES2 (0.50) | CES2CES1L3MBTL1KDM4EMAPT | |
| SCHEMBL6700713 | 0.81 | CES2 (0.50) | CES2CES1L3MBTL1KDM4EMAPT | |
| SCHEMBL6701419 | 0.79 | CES2 (0.66) | CES2CES1L3MBTL1KDM4EMAPT | |
| SCHEMBL6701425 | 0.79 | CES2 (0.66) | CES2CES1L3MBTL1KDM4EMAPT | |
| SCHEMBL19994724 | 0.78 | CES2 (0.46) | CES2CES1KDM4EMAPTMAOB | |
| SCHEMBL13209732 | 0.78 | MAPT (0.47) | CES2CES1KDM4EMAPTKMT2A | |
| SCHEMBL13576765 | 0.78 | MAPT (0.47) | CES2CES1KDM4EMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040077895-A1 | Process for the preparation of strobilurin intermediates | WADITSCHATKA RUDOLF (CH) | 2004-04-22 | — | — | US | disclosed |
| US-6664422-B1 | Process for the preparation of strobilurin intermediates | BAYER AKTIENGESELLSCHAFT (DE) | 2003-12-16 | — | — | US | disclosed |
| EP-1137627-A1 | PROCESS FOR THE PREPARATION OF STROBILURIN INTERMEDIATES | Bayer Aktiengesellschaft (DE) | 2001-10-04 | — | — | EP | disclosed |
| WO-2000034229-A1 | PROCESS FOR THE PREPARATION OF STROBILURIN INTERMEDIATES | BAYER AKTIENGESELLSCHAFT (DE) | 2000-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077895-A1 | Process for the preparation of strobilurin intermediates | TET1, CYP1B1, STS | CES2 1780/4885CES1 1221/4885L3MBTL1 2453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.